Valnevaの空売り状況は、投資家がValnevaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Valneva (NASDAQ:VALN) 株価情報, 空売り情報

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Valneva SE

News

RNTX

Rein Therapeutics To Present New Data On Caveolin Scaffolding Peptides In IPF And Normal Lung Samples At ATS 2025

JP Morgan analyst Michael Mueller initiates coverage on Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Overweight rating and announces Price Target of $36.

Price Target

Initiation

Analyst Ratings

JP Morgan Initiates Coverage On Smartstop Self Storage with Overweight Rating, Announces Price Target of $36

YJUVEK approved for the treatment of DEB from birth in Europe
Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional
Krystal Biotech, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK&#xAE; (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. VYJUVEK is the first corrective medicine approved in Europe for the treatment of DEB. The approval granted by the EC allows for flexible VYJUVEK dosing either at home or in healthcare setting, with the option for patient or caregiver administration if deemed appropriate by a healthcare professional.
This EC decision authorizes the marketing of VYJUVEK in all European Union member states, as well as Iceland, Norway and Liechtenstein. The timing for availability of VYJUVEK in individual countries will depend on multiple factors, including the completion of reimbursement procedures. The Company is planning for its first European launch in Germany in mid-2025.
"Today's approval is an exciting milestone for Krystal and the patients we aim to serve. After years of preparation in close coordination with leading DEB treatment centers, we are ready and excited to bring this urgently needed therapy to patients," said Laurent Goux, Senior Vice President and General Manager of Europe at Krystal Biotech. "With already 1,000 DEB patients identified in France and Germany, as well as many more across the continent, our goal is clear – to ensure as many patients as possible are able to benefit from sustainable access to VYJUVEK."

Biotech

General

KRYS

Krystal Biotech Receives European Commission Approval Of VYJUVEK For The Treatment Of Dystrophic Epidermolysis Bullosa

2025 Financial Outlook
Management provided an outlook for the full year of 2025 ending December 31, 2025. Based on our current estimates, management expects:
<ul>
<li>Revenues between $395 to $405 million</li>
<li>Non-GAAP gross margin between 78% and 80%, compared to previous guidance of 80% to 82%</li>
<li>Non-GAAP income from operations to be between $101 million and $106 million, compared to previous guidance of $130 million to $135 million</li>
</ul>

Guidance

INMD

InMode Affirms FY2025 Sales Guidance of $395.00M-$405.00M vs $393.38M Est

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy
CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors

GLUE

Monte Rosa's MRT-51443 Demonstrates Potent CDK2 Degradation And Delays Resistance To CDK4/6 Inhibitors In Preclinical Studies

XRTX

XORTX Announces Receipt Of Patent For Xanthine Oxidase Inhibitor Formulations By European Patent Office

Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.24 by 12.5 percent. This is a 58.82 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $142.72 million which beat the analyst consensus estimate of $131.36 million by 8.65 percent. This is a 40.10 percent increase over sales of $101.87 million the same period last year.

Earnings

Earnings Beats

OPRA

Opera Q1 Adj. EPS $0.27 Beats $0.24 Estimate, Sales $142.72M Beat $131.36M Estimate

InMode Q1 Adj. EPS $0.31 Misses $0.35 Estimate, Sales $77.87M Miss $78.21M Estimate

Outlines strong operational and financial performance driven by the Company's transformative strategy
Warns that Elliott's high-risk proposals are misleading, based on flawed analysis and threaten long-term shareholder value
Underscores the valuable skills and experiences Phillips 66's Board and nominees have to drive shareholder value creation, superior to those of Elliott's nominees
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) (the "Company") today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its upcoming Annual Meeting of Shareholders on May 21, 2025.
In conjunction with the presentation, Phillips 66 published two new videos that showcase the skills and experiences the Company's two new Board nominees, A. Nigel Hearne and Howard Ungerleider, would bring to the Board and how they would approach driving shareholder value as a potential Board member of Phillips 66.
The presentation and the videos are available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phillips66delivers.com&amp;esheet=54244480&amp;newsitemid=20250427721989&amp;lan=en-US&amp;anchor=www.phillips66delivers.com&amp;index=1&amp;md5=da7ce40342b0431b228bfc94fbd4636d">www.phillips66delivers.com</a>.
Highlights of the investor presentation include:
Phillips 66's proven strategy has driven, and will drive, outperformance for shareholders
<ul>
<li>Since Mark Lashier became President and CEO in 2022, Phillips 66 has delivered total shareholder returns of 67%1, significantly outperforming the S&amp;P 500 Energy Index by 45%1 and the Company's synthetic proxy peer median2 by 42%1</li>
<li>In under three years, Phillips 66 has taken significant action, including returning over $14 billion to shareholders through share repurchases and dividends, rationalization of Refining assets, $3.5 billion in non-core asset divestitures, and opportunistic Midstream expansion through the Pinnacle and EPIC NGL acquisitions3</li>
<li>Reduced Refining Adjusted Controllable Costs from $6.98/bbl in 2022 to $5.90/bbl4 in 2024 with a clear plan in place to further reduce costs and achieve $5.50/bbl by 20275</li>
<li>Phillips 66's transformative strategy is in its early innings and has significant room to deliver further value. This proven strategy will continue to drive long-term competitiveness in Refining, grow the NGL value chain, maintain the Company's advantaged position in Chemicals, optimize profitability across all assets, and deliver consistent, compelling returns
<ul>
<li>Phillips 66 has delivered Refining profitability on par with peers on a like-for-like basis, while outperforming them in overall Refining cost improvements since 2022 6. The Company remains focused on cost improvements with a focus on further enhancing market capture.</li>
<li>Compared to 2021, our projected Midstream Adjusted EBITDA (post EPIC NGL) has grown by $1.9 billion, driven by an incremental 18% Cash Return on Capital Invested7, with additional organic growth opportunities in the future</li>
<li>CPChem's global scale and feedstock advantages result in a self-funding joint venture with stable, growing distributions that is constructing two world-scale projects coming online in late 2026</li>
</ul>
</li>
</ul>
The Company's integrated model creates consistent and compelling long-term value for shareholders
<ul>
<li>Compared to the weighted proxy peer average, the Company's integrated model delivers higher returns for shareholders and lower volatility across cycles</li>
<li>Phillips 66's integrated structure creates $500 million in annual operating synergies8, as the Midstream business ensures reliable supply and integrated logistics for refineries and CPChem, ultimately improving flow assurance, feedstock quality, blending efficiency, and market flexibility</li>
<li>Since the spinoff in 2012, we have grown our dividend at a 15% CAGR.9 Our annual dividend paid has increased every year – a rare achievement in the energy sector, especially through economic and commodity cycles</li>
</ul>

Phillips 66 Files Investor Presentation Highlighting Strategy, Board Strength, and Path For Shareholder Value Creation

JP Morgan analyst Jeffrey Zekaukas downgrades Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Overweight to Neutral and lowers the price target from $112 to $76.

Downgrades

JP Morgan Downgrades Eastman Chemical to Neutral, Lowers Price Target to $76

Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.50 by 14 percent. This is a 52.89 percent decrease over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $540.47 million which missed the analyst consensus estimate of $552.05 million by 2.10 percent. This is a 17.07 percent decrease over sales of $651.70 million the same period last year.

Earnings Misses

ARLP

Alliance Res Partners Q1 EPS $0.57 Beats $0.50 Estimate, Sales $540.47M Miss $552.05M Estimate

ADMA

ADMA Biologics Announces FDA Approval Of Its Yield Enhancement Production Process

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is looking for Q2 GAAP EPS of $3.33-$3.37 vs $3.45 analyst estimate..

Roper Techs Sees Q2 GAAP EPS $3.33-$3.37 vs $3.45 Est

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) lowers FY2025 GAAP EPS guidance from $14.21-$14.46 to $13.72-$13.97 vs $14.19 analyst estimate..

Roper Techs Lowers FY2025 GAAP EPS Guidance from $14.21-$14.46 to $13.72-$13.97 vs $14.19 Est

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is looking for Q2 Adj EPS of $4.80-$4.84 vs $4.86 analyst estimate..

Roper Techs Sees Q2 Adj EPS $4.80-$4.84 vs $4.86 Est

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) raises FY2025 Adj EPS guidance from $19.75-$20.00 to $19.80-$20.05 vs $19.92 analyst estimate. Raises FY2025 sales outlook from $7.74 billion to $7.88 billion vs $7.74 billion estimate.

Roper Techs Raises FY2025 Adj EPS Guidance from $19.75-$20.00 to $19.80-$20.05 vs $19.92 Est; Raises FY2025 Sales Guidance from $7.74B to $7.88B vs $7.74B Est

Jefferies analyst Joe Dickstein initiates coverage on American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Buy rating and announces Price Target of $37.

Jefferies Initiates Coverage On American Healthcare REIT with Buy Rating, Announces Price Target of $37

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building and leading the company's 50-country operating platform. As part of this planned transition, Dr. Backstrom will serve as a strategic advisor, working closely with the company's executive team and Board of Directors.
Scholar Rock also announced today the addition of three leaders with unparalleled experience and success in building global organizations focused on developing and commercializing life-changing therapies.
<ul>
<li>Akshay Vaishnaw, M.D., Ph.D., has been named President of R&amp;D; he was formerly President of Alnylam.</li>
<li>R. Keith Woods has been appointed Chief Operating Officer and will focus on evolving the organization into a fully integrated global enterprise; he was formerly COO of argenx.</li>
<li>Vikas Sinha is joining as Chief Financial Officer; he was formerly CFO of Alexion and ElevateBio.</li>
</ul>
"On behalf of the Board, we are deeply grateful to Jay for his leadership over the past three years - driving us through the highly successful apitegromab global Phase 3 program and now into the US and European regulatory processes for marketing authorization," said Mr. Hallal. "As Board Chair, I have been continuously collaborating with Jay to accelerate Scholar Rock's evolution into a global biotech leader. These efforts will be amplified by the immediate addition of Akshay, Keith and Vikas - three operators that have built and led some of the most successful biotech companies in our industry. Together, we are committed to realizing Scholar Rock's global ambitions to bring apitegromab to SMA patients around the world."
"It has been an honor to lead the incredible team at Scholar Rock over the past several years. I am very proud of all we have achieved - from advancing apitegromab through a successful, pivotal Phase 3 study and on the path to becoming a commercial company," said Dr. Backstrom. "With the BLA now accepted under priority review and the anticipated launch later this year, this is the right moment for our leadership transition. I'm grateful for the close partnership over the years with David and Akshay as board members, and I look forward to continuing our collaboration on behalf of the SMA community to bring our highly innovative apitegromab, the world's first muscle targeted treatment, to patients and families living with the impact of this severe and progressive disease."

Management

SRRK

Scholar Rock Names Vikas Sinha as CFO, Keith Woods as COO Amid Big Biotech Expansion Plans

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported quarterly earnings of $4.78 per share which beat the analyst consensus estimate of $4.74 by 0.84 percent. This is a 8.39 percent increase over earnings of $4.41 per share from the same period last year. The company reported quarterly sales of $1.88 billion which beat the analyst consensus estimate of $1.82 billion by 3.20 percent. This is a 12.02 percent increase over sales of $1.68 billion the same period last year.

Roper Techs Q1 Adj. EPS $4.78 Beats $4.74 Estimate, Sales $1.88B Beat $1.82B Estimate

Canaccord Genuity analyst Edward Nash initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announces Price Target of $64.

Comments

Valneva

空売り

Valneva (NASDAQ:VALN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル